{
    "2018-07-01": [
        [
            {
                "time": "",
                "original_text": "【川财研究*医药生物】泰格医药（300347）：内生持续高增长，汇兑损益或缩窄——2018年半年度业绩预告点评",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "内生增长",
                        "汇兑损益",
                        "业绩预告",
                        "2018年半年度"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[买入评级] 泰格医药(300347)：中报业绩超预期 推进方达医药香港上市",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "买入评级",
                        "中报业绩",
                        "超预期",
                        "方达医药",
                        "香港上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}